Modeling Endoscopic Improvement after Induction Treatment with Mesalamine in Patients with Mild-to-Moderate Ulcerative Colitis
Endoscopic improvement is an important treatment target for mild-to-moderate ulcerative colitis (UC). However, early endoscopic evaluation is not always feasible. We aimed to develop a clinical decision support tool to discriminate patients who have achieved endoscopic improvement from those with more severe inflammation following mesalamine induction therapy. (Source: Clinical Gastroenterology and Hepatology)
Source: Clinical Gastroenterology and Hepatology - December 3, 2020 Category: Gastroenterology Authors: Christopher Ma, Jenny Jeyarajah, Leonardo Guizzetti, Claire E. Parker, Siddharth Singh, Parambir S. Dulai, Geert R. D ’Haens, William J. Sandborn, Brian G. Feagan, Vipul Jairath Source Type: research
Reply
We thank Wang and colleagues for their interest in our retrospective cohort study.1 In their letter, they offer 2 suggestions to improve the interpretability of the main results of our study that inflammatory bowel diseases (IBD) are associated with chronic kidney disease (CKD) and that mesalamine is not associated with reduced estimated glomerular filtration rate. (Source: Clinical Gastroenterology and Hepatology)
Source: Clinical Gastroenterology and Hepatology - November 19, 2020 Category: Gastroenterology Authors: Ravy K. Vajravelu, Lawrence Copelovitch, Michelle R. Denburg Tags: Letter to the Editor Source Type: research
A Case of Lung Abscess Caused by Double Immunosuppressive Therapy to Treat Ulcerative Colitis.
Abstract
A 25-year-old man was admitted to our institution for remission induction therapy to treat a 12-year condition of ulcerative colitis (UC). Previously, he was treated with drugs, such as mesalamine, immunomodulators, prednisolone (PSL), and anti-TNFα anti-body, but remission was not maintained. Therefore, we started remission induction therapy with 20 mg/day of tofacitinib (TOF) to inhibit the action of Janus kinase. On the 29th day after TOF administration, he developed a lung abscess with high fever. A chronic bulla was already present in his lung; therefore, the lung abscess was likely formed d...
Source: Medicina (Kaunas) - November 7, 2020 Category: Universities & Medical Training Authors: Tominaga K, Kanazawa M, Tanaka T, Kojimahara S, Sugaya T, Watanabe S, Yamamiya A, Majima Y, Iijima M, Goda K, Irisawa A Tags: Medicina (Kaunas) Source Type: research
Ulcerative Colitis-Diagnostic and Therapeutic Algorithms.
CONCLUSION: A wide variety of drugs are now available for the treatment of ulcerative colitis, enabling the individualized choice of the best treatment for each patient. Regular surveillance colonoscopies to rule out colon carcinoma should be scheduled at intervals that depend on risk stratification.
PMID: 33148393 [PubMed - in process] (Source: Deutsches Arzteblatt International)
Source: Deutsches Arzteblatt International - November 6, 2020 Category: General Medicine Tags: Dtsch Arztebl Int Source Type: research
The Therapeutic Effect of Shark Liver Oil in a Rat Model of Acetic Acid-Induced Ulcerative Colitis.
We examined the oxidative stress indices, histopathological features, and body weight changes, as well as the function of the liver and kidneys at the end of treatment. Administration of 10% rectal and 400 mg oral SLO resulted in a significant weight gain. Also, glutathione peroxidase activity was significantly higher in 5% and 10% SLO-treated groups, and elevated superoxide dismutase activity in rats that received 5% SLO was observed compared to negative control and Asacol groups. While no significant changes were observed in most of the kidney and liver function markers, higher levels of aspartate aminotransferase were...
Source: Evidence-based Complementary and Alternative Medicine - November 6, 2020 Category: Complementary Medicine Tags: Evid Based Complement Alternat Med Source Type: research
Biologic Therapy in Elderly Patients with IBD: Current Trends and Special Management Considerations
AbstractPurpose of reviewWith the aging IBD population and increasing incidence of elderly-onset IBD, the overall prevalence of IBD in the elderly is rising. The elderly have unique medical, psychosocial, and other age-related comorbidities and disabilities that need to be taken into account when assessing the impact of IBD on the patient ’s overall health and quality of life, and choosing an effective therapy.Recent findingsThere is a general reluctance among physicians to prescribe biologic therapies out of concerns of their potential side effects, in favor of mesalamine, steroids, and surgery. Although there is an ove...
Source: Current Treatment Options in Gastroenterology - October 23, 2020 Category: Gastroenterology Source Type: research
Ileal Signet Ring Cell Carcinoma Masked by Crohn Disease.
Conclusion: This case of metastatic ileal SRCC occurred in the setting of long-standing, clinically controlled CD. Although the absolute risk of small-bowel adenocarcinoma in CD is low, active surveillance for small-bowel adenocarcinoma in patients with longstanding CD may be prudent, given the overlapping symptomology of SRCC and CD, the aggressiveness of SRCC, and the association of SRCC with subclinical inflammation.
PMID: 33071669 [PubMed] (Source: Ochsner Journal)
Source: Ochsner Journal - October 20, 2020 Category: General Medicine Tags: Ochsner J Source Type: research
Blistering autoimmune skin reaction following SHINGRIX vaccination in an ulcerative colitis patient: Case report and literature review.
Abstract
Patients with inflammatory bowel disease, especially those on immunosuppressive therapy, are at higher risk of acquiring infectious diseases (Reich et al., 2016). For this reason, immunizations are routinely recommended in comprehensive inflammatory bowel disease care. SHINGRIX, a non-live recombinant herpes zoster vaccine, was approved by the Food and Drug Administration in 2017. Adults aged 50 and over are recommended to receive two doses of SHINGRIX. Unlike ZOSTAVAX® which is a live zoster vaccine that has been in use since 2006, SHINGRIX is safe for those on immunosuppression (Reich et al., 2...
Source: Vaccine - October 13, 2020 Category: Allergy & Immunology Authors: Bell H, Kamal N, Wong U Tags: Vaccine Source Type: research
Mesalamine in the Initial Therapy of Ulcerative Colitis
Inflammatory bowel disease is a chronic disorder of intestinal inflammation and includes Crohn ’s disease and ulcerative colitis. The goal of therapy is to induce and maintain remission, which is achieved with conventional therapies. Mesalamine is considered a first-line therapy for ulcerative colitis. Clinical trials have confirmed its efficacy and safety in patients with mild to moderate ulcerative colitis. Doses of more than 2.4 g/d achieve significantly higher rates of clinical and endoscopic remission, with a decreased risk of relapse. Serious adverse effects are rare, but nonadherence is common. Mesalamine is cons...
Source: Gastroenterology Clinics of North America - September 23, 2020 Category: Gastroenterology Authors: Richa Chibbar, Alan C. Moss Source Type: research
Temporal trend of disease recognition, treatment paradigm, and clinical outcomes of Crohn disease in Thailand from 2000 through 2017: Is early use of thiopurines beneficial?
The prevalence of Crohn disease (CD) is increasing in Asia, but data from Southeast Asian population are scarce.
The databases of 2 university-based national tertiary referral centers located in Bangkok, Thailand, were retrospectively reviewed for adult patients diagnosed with CD during January 2000 to December 2017. Disease characteristics, diagnosis, treatment, and outcomes were described and compared between the 2000 to 2009 cohort (cohort A) and the 2010 to 2017 cohort (cohort B).
One hundred eighty-two patients (mean age: 46.4 years, 50% male) with 993 patient-years of follow-up were included. Thirteen percent had a...
Source: Medicine - September 18, 2020 Category: Internal Medicine Tags: Research Article: Observational Study Source Type: research
Protective Effect of Vitis vinifera (Black Grape) Seed Extract and Oil on Acetic Acid ‑Induced Colitis in Rats
Conclusions: Oral administration of BGSE and BGSO had an appropriate anti ‑inflammatory effect and so could be considered as a suitable candidate for treating or preventing ulcerative colitis. Furthermore, detailed studies are warranted to explore the exact mechanism of action and clinical preference of these compounds. (Source: International Journal of Preventive Medicine)
Source: International Journal of Preventive Medicine - September 9, 2020 Category: International Medicine & Public Health Source Type: research
The endogenous ligand for guanylate cyclase-C activation reliefs intestinal inflammation in the DSS colitis model.
Abstract
Ulcerative colitis (UC) is a major type of inflammatory bowel disease (IBD) and significantly impacts patient quality of life. Previous research revealed that the guanylate cyclase-C (GC-C) signaling pathway is associated with the severity of UC. We aimed to investigate the effect of the GC-C agonist, guanylin (Gn), on inflammatory injury in mice with colitis. An experimental UC model was established in Balb/c mice. Mesalamine served as a positive control. The Gn overexpression vector was administered once per day for 1 week. Intestinal permeability of the mice was measured using fluorescein isoth...
Source: Acta Biochim Pol - September 6, 2020 Category: Biochemistry Authors: Lan D, Wen Y, Dong X, Yang Q, Liu Y, Wang K, Li H, Miao Y Tags: Acta Biochim Pol Source Type: research
Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis.
CONCLUSIONS: There is high-certainty evidence that 5-ASA is superior to placebo for maintenance therapy in UC. There is high-certainty evidence that 5-ASA is inferior compared to SASP. There is probably little or no difference between 5-ASA and placebo, and 5-ASA and SASP in commonly reported AEs such as flatulence, abdominal pain, nausea, diarrhea, headache, and dyspepsia. Oral 5-ASA administered once daily has a similar benefit and harm profile as conventional dosing for maintenance of remission in quiescent UC.
PMID: 32856298 [PubMed - in process] (Source: Cochrane Database of Systematic Reviews)
Source: Cochrane Database of Systematic Reviews - August 27, 2020 Category: General Medicine Authors: Murray A, Nguyen TM, Parker CE, Feagan BG, MacDonald JK Tags: Cochrane Database Syst Rev Source Type: research
Xylan microparticles for controlled release of mesalamine: Production and physicochemical characterization
Publication date: Available online 17 August 2020Source: Carbohydrate PolymersAuthor(s): Silvana Cartaxo da Costa Urtiga, Vitória Maria Oliveira Alves, Camila de Oliveira Melo, Marini Nascimento de Lima, Ernane Souza, Arcelina Pacheco Cunha, Nágila Maria Pontes Silva Ricardo, Elquio Eleamen Oliveira, Eryvaldo Sócrates Tabosa do Egito (Source: Carbohydrate Polymers)
Source: Carbohydrate Polymers - August 19, 2020 Category: Biomedical Science Source Type: research
Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.
CONCLUSIONS: There is high-certainty evidence that 5-ASA is superior to placebo, and moderate-certainty evidence that 5-ASA is not more effective than SASP. Considering relative costs, a clinical advantage to using oral 5-ASA in place of SASP appears unlikely. High-certainty evidence suggests 5-ASA dosed once daily appears to be as efficacious as conventionally-dosed 5-ASA. There may be little or no difference in efficacy or safety among the various 5-ASA formulations.
PMID: 32786164 [PubMed - in process] (Source: Cochrane Database of Systematic Reviews)
Source: Cochrane Database of Systematic Reviews - August 11, 2020 Category: General Medicine Authors: Murray A, Nguyen TM, Parker CE, Feagan BG, MacDonald JK Tags: Cochrane Database Syst Rev Source Type: research
